A compound of formula ##STR1## where R.sup.1 is hydrogen or a protecting group Q; R.sup.2 is hydrogen, a C.sub.1 -C.sub.8 aliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.7 -C.sub.13 araliphatic radical, an alkali metal ion or an ammonium ion; R.sup.3 and R.sup.4 are independently hydrogen, halogen or hydroxy; R.sup.5 is C.sub.6 -C.sub.10 aryloxythiocarbonyloxy, the C.sub.6 -C.sub.10 aryl group being unsubstituted or substituted, or R.sup.5.sub.a ; R.sup.5.sub.a is hydrogen, fluorine, chlorine, hydroxy, --OR.sup.8, --OCOR.sup.8 or silyloxy substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups; R.sup.6 is hydrogen, a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.6 -C.sub.15 aromatic radical, a C.sub.7 -C.sub.16 araliphatic radical, --COR.sup.9, --SO.sub.2 R.sup.9 or silyl substituted by three C.sub.1 -C.sub.15 hydrocarbyl groups; R.sup.7 is a monovalent nucleoside base radical, hydroxyl, --OR.sup.8 or --OCOR.sup.8, and R.sup.9 are independently a C.sub.1 -C.sub.10 aliphatic radical, a C.sub.3 -C.sub.8 cycloaliphatic radical, a C.sub.6 -C.sub.15 aromatic radical or a C.sub.7 -C.sub.16 araliphatic radical; or R.sup.5 and the indicated R.sup.6 O-together denote an isopropylidenedioxy group or R.sup.5 and R.sup.7 together denote an isopropylidenedioxy group, provided that when R.sup.5 and R.sup.7 together denote isopropylidenedioxy, R.sup.1 R.sup.2, R.sup.3 R.sup.4 and R.sup.6 are not all hydrogen. The disclosure further relates to a method of preparing the compounds of formula I by reacting a olefinic acetonide with a phosphinate compound and to the use of the compounds of formula I as pharmaceutical agents.
化合物的
化学式为##STR1##其中,R.sup.1是氢或保护基Q;R.sup.2是氢,C.sub.1-C.sub.8脂肪基,C.sub.6-C.sub.15芳香基,C.sub.3-C.sub.8环脂肪基,C.sub.7-C.sub.13芳基脂肪基,碱
金属离子或
铵离子;R.sup.3和R.sup.4独立地是氢,卤素或羟基;R.sup.5是C.sub.6-C.sub.10芳氧
硫酰氧基,其中C.sub.6-C.sub.10芳基未取代或取代,或R.sup.5.sub.a; R.sup.5.sub.a是氢,
氟,
氯,羟基,--OR.sup.8,--OCOR.sup.8或被三个C.sub.1-C.sub.15烃基取代的
硅氧基;R.sup.6是氢,C.sub.1-C.sub.10脂肪基,C.sub.6-C.sub.15芳香基,C.sub.7-C.sub.16芳基脂肪基,--COR.sup.9,--SO.sub.2R.sup.9或被三个C.sub.1-C.sub.15烃基取代的
硅基;R.sup.7是一价的核苷酸基团,羟基,--OR.sup.8或--OCOR.sup.8,R.sup.9独立地是C.sub.1-C.sub.10脂肪基,C.sub.3-C.sub.8环脂肪基,C.sub.6-C.sub.15芳香基或C.sub.7-C.sub.16芳基脂肪基;或R.sup.5和所指示的R.sup.6 O共同表示异丙基二氧基基团或R.sup.5和R.sup.7共同表示异丙基二氧基基团,但当R.sup.5和R.sup.7共同表示异丙基二氧基时,R.sup.1,R.sup.2,R.sup.3,R.sup.4和R.sup.6不全为氢。本发明还涉及一种通过将烯丙基乙
酮酸酯与
磷酸酯化合物反应制备化合物I的方法,以及将化合物I用作制药剂的用途。